Search > Ovarian Cancer
180 Participants NeededMy employer runs this trial

ARR-002 for Ovarian and Endometrial Cancer

Recruiting at 5 trial locations
CO
Overseen ByClinical Operations
Age: 18+
Sex: Female
Trial Phase: Phase 1
Sponsor: ArriVent BioPharma, Inc.
Must not be taking: Auristatin drugs, Anticoagulants
Disqualifiers: Hepatitis, HIV, Diabetes, ILD, others
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This is a Phase 1 study to assess safety, tolerability, pharmacokinetics, immunogenicity, and antitumor activity of ARR-002 in advanced or metastatic ovarian or endometrial cancer.

Are You a Good Fit for This Trial?

This trial is for adults with advanced or metastatic ovarian, primary peritoneal, or fallopian tube cancer that has not responded to standard treatments. Participants must be in good general health, have a life expectancy of at least 12 weeks, and meet specific lab criteria. Certain eye conditions, infections, other cancers, or recent therapies may exclude participation.

Inclusion Criteria

Life expectancy of at least 12 weeks
Patients must have at least one measurable lesion according to RECIST v1.1
I have a tumor sample available or will agree to a biopsy.
See 4 more

Exclusion Criteria

I have had or currently have interstitial lung disease caused by medication.
I have serious eye conditions like keratitis or corneal ulcers.
I have fluid buildup in my chest, abdomen, or pelvis that is not well controlled.
See 14 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Phase 1a Treatment

Dose-escalation portion to assess the safety and tolerability of ARR-002 in participants with platinum-resistant ovarian cancer

21 days

Phase 1b Treatment

Cohorts of participants by cancer type (platinum-resistant ovarian cancer and endometrial cancer) receive treatment to assess safety, tolerability, and preliminary antitumor activity

Up to 24 months

Follow-up

Participants are monitored for safety and effectiveness after treatment

30 days after the last dose

What Are the Treatments Tested in This Trial?

Interventions

  • ARR-002

Trial Overview

The study is testing the safety and effects of a new drug called ARR-002 in people with advanced ovarian or endometrial cancer. It’s an early-phase (Phase 1) trial focused on finding safe doses and understanding how the drug behaves in the body.

How Is the Trial Designed?

1

Treatment groups

Experimental Treatment

Group I: ARR-002Experimental Treatment1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

ArriVent BioPharma, Inc.

Lead Sponsor

Trials
2
Recruited
550+

Unbiased Results

We believe in providing patients with all the options.

Your Data Stays Your Data

We only share your information with the clinical trials you're trying to access.

Verified Trials Only

All of our trials are run by licensed doctors, researchers, and healthcare companies.